1. Scrip
  2. >>Conferences
  3. >>ASH

ASH: Despite Novel Drugs In CML, Older Agents Are Tough To Dislodge

Superiority Data Vs. Generic Options

 
• By Alaric DeArment

Scemblix proved more efficacious than older TKIs, but the older drugs may maintain a presence for economic reasons, though Takeda’s Iclusig may see a diminished role due to tolerability concerns.

(Alaric DeArment/Scrip)
Key Takeaways
  • Longer-term follow-up data from a Phase III trial at ASH showed Scemblix has much better efficacy than first- and second-generation TKIs for CML after 96 weeks of treatment.
  • Still, an investigator in the study said economic considerations may result in the older drugs continuing to play a role in first-line CML treatment.
  • Meanwhile, Takeda’s Iclusig is likely to see a diminished role due to tolerability concerns, but the drug maker has an option to license olverembatinib, which in Phase Ib data showed efficacy in patients with resistance to Iclusig and Scemblix.

Despite emerging data at the American Society of Hematology annual meeting that supports the use of Novartis’s tyrosine kinase inhibitor Scemblix (asciminib) in first-line chronic myeloid leukemia (CML), older and increasingly generically available drugs may continue to play a significant role due to potential cost considerations

Novartis presented data from the Phase III ASC4FIRST at ASH on 8 December, while Takeda presented long-term follow-up

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ASH

Sweden’s Mendus Clears Regulatory Path For Vididencel Registration Trial

 
• By Kevin Grogan

Following promising Phase II data presented at ASH on the company's allogenic leukemia-derived dendritic cell vaccine, Mendus has secured support from the FDA and the EMA for pivotal studies starting later this year.

ASH: AbbVie/Genmab Look To Stake Anti-CD20 Bispecific Claim In CLL

 
• By Alaric DeArment

Data presented at the ASH conference showed high overall response and complete response rates in heavily pretreated CLL patients with Epkinly.

ASH: How Should BCMA-Directed Bispecifics Fit Into Myeloma Treatment?

 
• By Alaric DeArment

With two products on the market, a third on the way and a fourth under development too, the question becomes how they will fit in relative to each other and also CAR-T cell therapies.

ASH: Out With The Old, In With The New As BMS Ushers In CELMoD Class

 
• By Alaric DeArment

BMS presented Phase I/II data for its next-generation small molecule drugs mezigdomide and iberdomide at ASH.

More from R&D

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.